This result was concordant with the frequency of TP53 mutations in a pooled premenopausal breast cancer cohort (41.5%), compared to a frequency of 32.9% in pooled postmenopausal breast cancer cohort (Midha et al., 2020). The gene discussed is TP53; the disease is breast carcinoma.